drugset / Trial / NCT01974258
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the maximum tolerated dose and dose-limiting toxicities of vemurafenib and/or cobimetinib when used with onartuzumab in cancer patients.
Timeline
- Start
- 2014-02
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | — | Oral |
| Subject | Onartuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Vemurafenib | Small molecule | — | Oral |